Covid-19 Update

Greg Clark Excerpts

Monday 5th October 2020 Commons Chamber

[Matt Hancock]

On the core of the hon. Lady’s point, the assessment of the epidemic on the basis of the updated data is core to our approach to tackling the epidemic. The chief medical officer has analysed the new data, which we have now published—on coronavirus.data.gov.uk we can see the data, and that is on the corrected basis. Based on Joint Biosecurity Centre analysis, the CMO’s advice is that the assessment of the disease and its impact have not substantially changed. That is because the just under 16,000 cases were essentially evenly spread, so it has not changed the shape of the epidemic. It has changed the level, in terms of where we are finding the epidemic and in what sorts of groups.

The hon. Lady asks how many contacts have been contacted, as opposed to how many of the primary index cases. As I said, that is happening concurrently, so as soon as the index case has been contacted by Test and Trace and interviewed, the contacts are immediately contacted. As I said, we have got through 51% of the backlog over the weekend, and we have brought in more resources to complete that task.

[Greg Clark (Tunbridge Wells) (Con)]

My right hon. Friend and everyone in the House hopes that there will be a safe and effective vaccine available during the months ahead, but the head of the vaccines taskforce has said that she expects it to be available to only half of the population, concentrating on the over-50s and the most vulnerable. Is that the Secretary of State’s understanding? What are the implications for the other half of the population?

[Matt Hancock]

This is a very important question. The vaccines taskforce has done incredibly important work in supporting the scientific development and manufacture of vaccines and in procuring vaccines—six different types of vaccine—from around the world. The work of deploying a vaccine is for my Department, working with the NHS and the armed forces, who are helping enormously with the logistical challenge, and we will take clinical advice on the deployment of the vaccine from the Joint Committee on Vaccination and Immunisation. My right hon. Friend the Chair of the Science and Technology Committee will know that 10 days ago the JCVI published a draft prioritisation, and it will update that as more data becomes clear from the vaccine. That is the Government’s approach: to take clinical advice from the JCVI.